No abstract

Background and Objectives: A topic already widely investigated is the negative prognostic value regarding the extent of high sensitive troponin I (hs-TnI) increases among patients with myocardial infarction (MI) and obstructive coronary atherosclerosis compared to a group of patients with MI and non-obstructive coronary atherosclerosis (MINOCA). Thus, the aim of this study was to evaluate the prognostic value concerning the extent of hs-TnI increase on clinical outcomes among patients with a MINOCA working diagnosis. Materials and Methods: We selected 337 consecutive patients admitted to hospital with a working diagnosis of MINOCA. The patients were divided in three groups according to the extent of hs-TnI increase during hospitalization (increase ≤5-times above the limit of the upper norm, >5 and ≤20-times, and >20-times). The study endpoints included all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE; cerebral stroke and transient ischemic attacks, MI, coronary artery revascularization, either percutaneous coronary intervention or coronary artery bypass grafting and all-cause mortality). Results: During the mean follow-up period of 516.1 ± 239.8 days, using Kaplan–Meier survival curve analysis, significantly higher mortality rates were demonstrated among patients from the group with the greatest hs-TnI increase compared to the remaining groups (p = 0.01) and borderline values for MACCE (p = 0.053). Multivariable cox regression analysis did not confirm hs-TnI among factors related to increased MACCE or all-cause mortality rates. Conclusion: While a relationship between clinical outcomes and the extent of the hs-TnI increase among patients with a MINOCA working diagnosis remains, it does not seem to be not as strong as it is in patients with obstructive coronary atherosclerosis.

No abstract

Objectives: To simulate and compare the clinical and economic outcomes of selfmonitoring of blood glucose (SMBG) devices along ranges of accuracy from a German payer perspective. MethOds: We programmed a long-term type 1 diabetes natural history and treatment cost-effectiveness model. In phase one, using past in-silico evidence (UVa/Padova simulator, accepted by the Food and Drug Administration for pre-clinical studies), we associated changes in SMBG error to changes in HbA1c, and separately, changes in severe hypoglycemia and hyperglycemia requiring an inpatient stay. In phase two, using Markov cohort simulations, we estimated the lifetime clinical and economic outcomes based on a German payer perspective. The primary comparison was a SMBG device with strip price € 0.56 Euros and 10% error (exceeding accuracy requirements by International Organization for Standardization (ISO) 15197:2013) versus a SMBG device with the same strip price and 15% error (accuracy meeting ISO 15197:2013). Outputs for the average patient over a 5-year time horizon, discounted at 3% per annum, were severe hypoglycemic and hyperglycemic events requiring an inpatient stay, quality-adjusted life years (QALYs), and cost differences per patient. Results: Assuming the benefits translate into HbA1c improvements only, an SMBG device with 10% versus 15% error was associated with an increase of 0.023 QALYs and a cost savings of € 100 Euros per patient over 5 years. Assuming the benefits translate into reduced severe hypoglycemic and hyperglycemic events requiring an inpatient stay only, an SMBG device with 10% versus 15% error was associated with a combined decrease in severe hypoglycemic and hyperglycemic events of 0.86 and cost savings of € 976 Euros per patient over 5 years. cOnclusiOns: Investing in devices with improved accuracy (less error) appears to be an affordable strategy with improved quality of life for type 1 diabetes patients. PMD67 coSt-effectIVeneSS of a PreVentIVe teStIng Strategy In relatIVeS of PatIentS wIth Brca MutateD oVarIan cancer VerSuS a no teSt StrategyObjectives: According to AIOM estimates, the prevalence rate of ovarian cancer is 1.3%. 8-13% of women diagnosed with epithelial OC have a germline BRCA1 or BRCA2 mutation. Specifically, the lifetime risk for OC in patients with BRCA1 mutations is 39-46% compared with 10-27% in patients with BRCA2 mutation. This study aims to estimate the cost-effectiveness ratio of a preventive testing strategy for relatives of patients with BRCA mutated cancer versus a no test strategy. MethOds: The BRCA testing pathway was elaborated by a panel of experts. Based on this, Cost-effectiveness analysis was carried out from the Italian National Health Service perspective through a decision analytic model, within 5 years times horizon. Two alternatives were considered: 1) Preventive BRCA testing for relatives of ovarian cancer patients with positive mutation BRCA1 and BRCA2; 2) No test . Cost and effectiveness data derived from literature were discounted by 3%. Costs were analyzed from Ital...

No abstract